How GLP-1 telehealth programs work: what to look for, what to avoid
Branded path or compounded path, month-to-month or locked in: the US GLP-1 telehealth programs that operate at meaningful scale differ less in the medicine than in the contract. Here is what good and bad programs look like, the five dimensions we score, and when a local clinic beats all of them.
A GLP-1 telehealth program is a licensed medical practice that prescribes remotely and ships medication from a partner pharmacy. Dozens operate at meaningful scale in the US in 2026. The branded path runs an insurance intake for Wegovy or Zepbound. The compounded path is cash-pay for semaglutide or tirzepatide prepared by a 503A or 503B compounding pharmacy a US-licensed pharmacy that prepares medication to a prescription; 503B is the larger FDA-registered outsourcing tier. We score every program on five dimensions and rank them on the homepage chart.
- Two paths: branded or compounded. Branded runs insurance; compounded is cash-pay, from about $149 a month at the cheapest program. About half the programs offer each; some offer both.
- Lock-in ranges from zero to six months. No-lock-in programs (Sesame, Hims, Ro) let you cancel anytime. Hard lock-in programs charge upfront and do not refund.
- Synchronous video visits are clinically richer. Asynchronous form-based intake reviewed by the prescriber on their own schedule is faster. Patients with complex medical history benefit from live visits.
- Five dimensions drive the score: pricing transparency, cancellation terms, onboarding speed, medication options, and member reviews. Full rubric at methodology.
- Programs are medical practices, not pharmacies. They operate under state telemedicine law. They do not hold medication inventory.
Key facts
| Dimension | What good looks like | What bad looks like | Where we score it |
|---|---|---|---|
| Pricing transparency | Maintenance-dose price published; labs, intake and shipping itemized | Starter-dose teaser; fees revealed at checkout | Price Index |
| Cancellation | Self-serve cancel inside the dashboard; no lock-in past current month | Phone-only cancel; six-month upfront non-refundable | Contract traps |
| Onboarding | Intake to first dose under 5 days; synchronous visit option | 14+ day delay; no clinician contact past initial form | Fastest programs |
| Medication options | Branded + compounded path; dose flexibility | Single tier; no titration support | Compounded vs branded |
| Member reviews | High public Trustpilot rating across many reviews | Low Trustpilot rating; complaints about delivery, support, billing | Methodology |
We score every program in the chart against these five dimensions, ten points each, weighted equally. Full methodology and rubric: scoring methodology.
What a GLP-1 telehealth program actually is
A GLP-1 telehealth program in 2026 is a US-based medical practice (often organized as a Professional Corporation or PC owned by physicians and contracted with a parent administrative entity) that operates remotely. The patient creates an account, completes a medical-history intake, has either an asynchronous review or a synchronous video visit with a licensed prescriber, and receives a prescription that is dispensed by a partner pharmacy. The medication ships to the patient, refrigerated where required. Most programs include ongoing prescriber availability for dose adjustment and side-effect management; some charge separately for follow-up visits.
How programs stay legal across state lines
The regulatory framework is state telemedicine law. Each prescriber must be licensed in the state where the patient lives. Programs achieve this through the Interstate Medical Licensure Compact (IMLCC) and through hiring networks of prescribers licensed in multiple states.
The DEA telemedicine rules for controlled substances (see the DEA proposed telemedicine rule) do not apply to GLP-1, because these molecules are not controlled. That simplifies the operational picture.
Programs are not pharmacies. They do not hold medication inventory directly, and they do not employ pharmacists. The partner pharmacy handles dispensing under the regulatory frameworks for 503A and 503B compounding (see FDA's compounding laws and policies).
Branded vs compounded path
The single biggest structural decision a program makes is whether to offer the branded path, the compounded path, or both. The branded path runs an insurance-pathway intake: the prescriber writes for Wegovy, Zepbound, Ozempic or Mounjaro, the program supports a prior authorization where coverage is available, and the medication ships from a retail or specialty pharmacy. Cost is whatever the patient's insurance copay is or whatever the cash-pay manufacturer-direct program (NovoCare, LillyDirect) charges.
The compounded path is cash-pay only. The prescriber writes for compounded semaglutide or tirzepatide, the prescription is dispensed by a 503A compounding pharmacy, and the patient pays the program's flat monthly fee. The branded path is the only path that produces an insurance-covered outcome. The compounded path is the only path that produces a predictable sub-$350 monthly cost.
The FDA published its position on these molecules' compounding eligibility in its semaglutide compounding statement and a parallel tirzepatide statement. More than half of the programs we track offer only one path; the rest offer both. See compounded vs FDA-approved semaglutide for the clinical distinction and generic semaglutide launch for the 2026 supply context. If you have already decided on compounded and want to choose by molecule rather than by program, our compounded medication index lists which programs offer which formulation. If you want to know which programs bundle medication into a flat monthly price (rather than charging it separately), see our complete list of programs that include medication in the price.
The five dimensions we score
Our methodology scores every program against five dimensions, ten points each, weighted equally. The scoring is published in full at methodology and the per-program score-sheet is on each program page.
- Pricing transparency. Maintenance-dose cost published, ongoing rate separated from introductory rate, lab and setup fees disclosed at the homepage rather than the checkout. A program that hides the maintenance price behind an intake gate scores low; a program that lists both starter and maintenance prices on the pricing page scores high.
- Cancellation terms. Self-serve cancellation in the patient dashboard with no phone-only friction. Lock-in past the current paid month is penalized in proportion to length and refundability. The contract-traps glossary at seven contract traps covers the full taxonomy.
- Onboarding experience. Time from intake start to first prescription. Quality of the clinical assessment (intake-form depth, presence of synchronous visit option). Friction at intake. Programs that ship the first dose within five business days score well; programs that take two weeks to first dose score low. Time-sensitive sort: fastest GLP-1 programs.
- Medication options. Branded availability, compounded availability, insurance pathway support, dose flexibility (can the patient hold or step back during titration). Programs that offer both branded and compounded with active dose flexibility score highest.
- Member reviews.The program's public Trustpilot rating, mapped to a 0-10 score, weighted above marketing copy. We read patient feedback for every program. When the verified-member feedback is sparse, we discount the score rather than score from marketing alone.
Lock-in terms decoded
Lock-in is the contract term that requires the patient to pay for a multi-month commitment upfront, often with limited refund rights. The taxonomy is small:
- No lock-in. True month-to-month or visit-by-visit.
- Soft lock-in. One to three month commitment, refundable on cancellation.
- Medium lock-in. Three to six months upfront, non-refundable after the first 14 days.
- Hard lock-in. Six months upfront, non-refundable, with auto-renewal.
- The worst variant. Hard lock-in with phone-only cancellation.
Programs that score highest on cancellation have either no lock-in or soft lock-in plus self-serve cancellation. The full breakdown is at what no lock-in actually means and the curated picks at best no-lock-in programs and best month-to-month programs. The contract patterns we have flagged across programs are at contract traps. For the verified program-by-program breakdown of which of the programs you can cancel anytime with no fee, and which bury a lock-in, see the no-fee cancellation list.
Synchronous vs asynchronous visits
Synchronous (live video) visits and asynchronous (form-based) intake serve different patient needs. Asynchronous is faster and works for healthy adults with straightforward obesity and no complicating medical history: the intake form captures the key clinical data, the prescriber reviews on their own schedule, and the prescription is written. Synchronous is clinically richer. The prescriber can ask follow-up questions, observe the patient, and address concerns in real time.
The 2020 to 2023 surge in telehealth volume was largely asynchronous (it scales better). The regulatory picture in 2024 to 2026 is gradually tilting back toward at least one synchronous visit before initial prescription; federal guidance lives at telehealth.hhs.gov and the CMS telehealth coverage page. California, New York, Texas and Florida have stricter state-level standards. Most programs now offer at least an optional synchronous visit; some require it. The clinical case for synchronous is in primary care vs telehealth.
How to evaluate a program before signing up
Five checks before paying anything.
- Find the maintenance-dose price, not the starter price. If the program does not publish it openly, that is a signal.
- Find the cancellation procedure (self-serve in the dashboard, or phone-only, or written notice required). Cancellation friction is the single best predictor of post-purchase regret.
- Identify the prescribing entity by name and confirm state licensure. Legitimate programs publish this.
- Identify the dispensing pharmacy by name. For compounded medication, confirm it is a US-based 503A pharmacy.
- Search Reddit, Trustpilot and the program-specific community feedback for billing, shipping and clinical-support complaints.
The red-flags checklist is at red flags checklist.
Signs of a bad program
Patterns that consistently predict poor outcomes:
- Phone-only cancellation.
- Opaque maintenance pricing.
- No synchronous visit option for a patient with any complicating history.
- No published prescriber name.
- Shipping from an unidentified pharmacy.
- Marketing language that promises specific weight-loss outcomes ("lose 20 pounds in 30 days").
- Aggressive auto-renewal.
- A refund policy that starts at "no refunds."
None of these are inherently illegal, but they consistently correlate with the lowest member-satisfaction scores in the chart. Reputable programs in the chart fail one or two of these checks at most; problem programs fail four or five.
What to do if your program raises prices
Programs do change prices, and the direction is not always up. Since mid-2025, several compounded programs cut their advertised entry prices while others restructured or moved patients to branded drugs. The 30-day notice is the standard. If the new price still beats your alternatives, accept and continue. If the new price puts the program above its peers, switch. Switching guidance is in switching from compounded to brand and the program-to-program switching path in when your insurance changes. Most programs will negotiate retention if asked, especially within 24 hours of cancellation; the bargaining room is small but real.
Switching programs without clinical discontinuity
Switching programs is straightforward when the new program is reputable. Bring three pieces of information to the new program's intake: current dose (semaglutide or tirzepatide milligrams per week), date of most recent injection, and titration history (which dose you started at, when you stepped up). The new program picks up the titration where the prior program left off; reputable programs do not force restart at the starter dose. The two-week gap during transfer is tolerable for most patients; longer gaps may require a brief restart at one dose below the current dose to retitrate. The clinical principle is dose continuity wherever possible.
When to use a local clinic instead
Local in-person care is the better default for several patient profiles:
- Complex medical history that benefits from a clinician who can see the full record: prior pancreatitis, heart failure, advanced kidney disease, type 1 diabetes, recent bariatric surgery.
- Need for an in-person physical examination (some commercial plans now require it).
- Existing relationship with an obesity medicine specialist or endocrinologist.
- Insurance coverage available at a local clinic but not through a telehealth program.
- Patient preference for in-person clinical relationships.
- Pediatric or adolescent patient (most telehealth programs are adults only).
The full comparison is in primary care vs telehealth GLP-1.
State telemedicine rules that affect program operation
Telemedicine rules vary by state, and the variation creates the patchwork of program availability across the US. The largest legal source is each state's Medical Practice Act and the state Medical Board's telemedicine policy. The Federation of State Medical Boards maintains a national tracker (see FSMB telemedicine policy summary). California, New York, Texas and Florida have stricter standards, typically requiring at least one synchronous visit and a documented clinician-patient relationship before prescription. Other states are more permissive.
Programs disclose their state availability on the signup flow; the gap-states (where a program does not operate) are captured in the chart's state-availability filter.
What the trial evidence supports about program delivery
Most randomized trial evidence on GLP-1 (STEP, SURMOUNT, SELECT, SURPASS) was generated under traditional in-person care; no large randomized trial has compared telehealth delivery head-to-head. Observational data from large telehealth networks suggests outcomes are broadly comparable when titration is well-managed, with the variance driven by patient factors (baseline BMI, adherence, lifestyle support) rather than delivery channel.
The behavioral support component of obesity care, where telehealth programs vary widely (some include intensive coaching, some include none), may matter more than the prescription itself for long-term outcomes. The STEP-3 trial (intensive behavioral therapy plus semaglutide) is published at JAMA; the SURMOUNT-1 trial is at NEJM. The trial backbone is the same regardless of delivery channel.
Program picks by buyer scenario
We do not recommend "the best program" in the abstract, because the right program depends on the patient scenario. Pick the cluster that matches yours:
- Cheapest cash-pay compounded: cheapest programs and under $200.
- Fastest time to first dose: fastest programs and fastest onboarding.
- No lock-in: no lock-in programs.
- Wegovy specifically (branded path): best for Wegovy. For Zepbound: best for Zepbound.
- Medicare cardiovascular indication: Medicare CV pathway. For Medicaid patients: Medicaid-friendly programs.
Specific program deep-dives at Mochi, Henry Meds, Hims, Ro, Form Health, Found, Calibrate, Ivim Health, Eden, LifeMD, Sesame Care, PlushCare, 9am Health and Knownwell.
What to do next
If you have a clear scenario in mind (cheapest, fastest, branded with insurance, no lock-in), pick the matching cluster page above and start there. The homepage chart ranks all programs against the same five dimensions and sorts by overall score and by maintenance-dose price; the methodology page walks through the rubric and the latest verified prices are at the Price Index. To compare any two programs side by side, open the GLP-1 program comparison chart. The companion pillars cover the other decisions: GLP-1 cost, GLP-1 insurance and the side effects and safety guide.
Frequently asked questions
What is a GLP-1 telehealth program?
A licensed medical practice that operates remotely. The patient completes an intake (typically online), a licensed prescriber reviews and either approves the GLP-1 prescription or requests additional information, and the medication ships from a partner pharmacy. The visit is either asynchronous (form-based, prescriber reviews on their own schedule) or synchronous (live video call). Most programs combine both.
Is a telehealth GLP-1 program as good as a local doctor?
It depends on the patient and the program. For a healthy adult with straightforward obesity and no complicating comorbidities, a quality telehealth program with synchronous visits is clinically equivalent to a primary care visit. For patients with complex medical history (heart failure, advanced kidney disease, prior pancreatitis, type 1 diabetes), local care with a clinician who knows the patient is usually better. We cover the trade-off in our explainer on primary care versus telehealth.
Branded or compounded? Which path do programs offer?
About half the programs offer branded medication only (Wegovy, Zepbound, Ozempic, Mounjaro) and run an insurance-pathway intake. The other half offer compounded semaglutide or tirzepatide cash-pay. A smaller subset offers both paths. We label every program's medication mix on its program page.
What does lock-in mean?
Most programs require an upfront commitment of one to six months. The shorter the commitment, the more flexibility the patient has if the program turns out to be a bad fit. Lock-in terms range from no commitment (Sesame Care visit-by-visit), to month-to-month (Hims, Ro), to three months upfront non-refundable (some compounded programs), to six months upfront with auto-renewal (a few legacy programs). We break down the contract traps in a separate guide.
Synchronous vs asynchronous: does it matter?
Synchronous (live video) visits are clinically richer; the prescriber can ask follow-up questions and observe the patient. Asynchronous (form-based) intake is faster and works fine for healthy adults with straightforward obesity. The 2020 to 2023 surge in telehealth volume was mostly asynchronous; the regulatory environment is gradually tilting back toward at least one synchronous visit before initial prescription, especially in California, New York and Texas.
How do I know a program is legitimate?
A legitimate program identifies the licensed prescribers and pharmacy by name, publishes pricing transparently with maintenance-dose cost (not just the teaser), permits cancellation without phone-only friction, ships medication that displays manufacturer labeling or 503A pharmacy labeling, and has a clear path for clinical questions beyond the initial intake. We keep a red-flags checklist for vetting a new program.
What happens if my program raises prices?
Programs adjust pricing periodically. The notice is typically 30 days. Patients are not locked in beyond the current paid period in most cases. The clinically continuous response is to either accept the new price, switch to a different program (titration continues at the new program from the current dose), or pause and reassess. We cover how to switch programs without restarting titration.
Can I switch programs without losing clinical continuity?
Yes. Bring your prescription details (current dose, date of most recent injection, titration history) to the new program's intake. Reputable programs accept new patients on existing doses without forcing restart. The two-week gap during transfer is typically tolerable; longer gaps may require a brief restart at a lower dose.
When should I use a local clinic instead?
Local care is the better default when you have complex medical history that benefits from a clinician who can see the full record, when you need a physical exam at intake (some plans now require it), when you have insurance coverage at a local clinic and not through telehealth, or when you prefer in-person clinical relationships. Local care is the worse default when geographic access is limited, when local clinicians do not have obesity medicine experience, or when scheduling delays are months.
